Outcomes
The financial part of Thallion risk is done.
Tax losses conversion is over.
We got what we wanted - no dilution and time to ride out this bear market.
Reduce cash burning. Thallion is bare bone now.
We wait on positive for Shigamabs, 4601 and 232.
I expect 232 arbitration to be resolved in Thallion 's favor with damages awarded against Expergen.
I also expect Shigamabs to finally get that green light and sign partnership agreement. Bioniche reported PIII vaccin results this week - positive and has indicated how lucrative E. Coli market is.
Now, 4601 is the star here.
I expect tumor skrinkage proof. The SP will soar if we get that. A quick take-over is after that the end game.
I'd say near 5$ per share.
Buyer = AstraZeneca.
Negative outcome, should trial fail. Thallion will fold and redistrute cash to shareholders. Sell assets and dividend it all out to us.
Caprion stake is 20% and Caprion is worth lotz of money. Covenant, caprion partner, just reported bullish earning results
Currently TLN is worth 0,46 cash per share excluding assets.,
Should the company fold, there is going to be a big dividend payout.
Yes the stock is trading at 25% cash value. Check around all micro biotech are trading at 25% cash value or so. So no worries for me as far as market valuation is concern
We will make money when Fundamental value is recognized by market. That day is soon. A few weeks... and we finally get those PIIa prem results.